Literature DB >> 24726267

Expression of cancer stem cell markers in basal and penta-negative breast carcinomas--a study of a series of triple-negative tumors.

Diego de Mendonça Uchôa1, Marcia Silveira Graudenz2, Sidia Maria Callegari-Jacques3, Carolina Rigatti Hartmann4, Bruna Pellini Ferreira5, Mariana Fitarelli-Kiehl6, Maria Isabel Edelweiss2.   

Abstract

PURPOSE: Breast cancer is a heterogeneous disease. Immunohistochemistry has given rise to triple-negative carcinoma (TNC). Concomitantly, biological origins of neoplasia and its heterogeneity has been strongly debated in cancer stem cells (CSC) theme. This study investigates the prevalence of basal (BCC) and penta-negative carcinomas (5NC) in TNC and establishes associations with CSC (CD44CD24).
MATERIALS AND METHODS: 94 TNC were tested for CK5/6, HER1, CD44 and CD24, evaluated by a simple immunohistochemistry score and correlated with clinicopathological and survival data.
RESULTS: BCC had higher tumor grades than 5NC (p=0.004). CD44 negativity (p=0.007) and CD44(-)CD24(+) phenotype (p=0.013) were associated with less vascular invasion amongst TNC. CD44 expression was associated with BCC (p=0.007). CD44(-)CD24(-/low) phenotype was associated with 5NC. None of the variables were associated with clinical outcome.
CONCLUSION: BCC and 5NC are closely related tumor subtypes. CD44(-)CD24(-/low) phenotype was associated with 5NC and CD44(-)CD24(+) phenotype was associated with vascular invasion. These results require histogenetic confirmation in larger studies.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Basal; Breast cancer; CD24; CD44; Triple-negative

Mesh:

Substances:

Year:  2014        PMID: 24726267     DOI: 10.1016/j.prp.2014.03.005

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  6 in total

1.  Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer.

Authors:  Justin D Lathia; Ofer Reizes; Praveena S Thiagarajan; Masahiro Hitomi; James S Hale; Alvaro G Alvarado; Balint Otvos; Maksim Sinyuk; Kevin Stoltz; Andrew Wiechert; Erin Mulkearns-Hubert; Awad Jarrar; Qiao Zheng; Dustin Thomas; Thomas Egelhoff; Jeremy N Rich; Huiping Liu
Journal:  Stem Cells       Date:  2015-05-15       Impact factor: 6.277

2.  KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.

Authors:  Mei Zhou; Prabhakar Pitta Venkata; Suryavathi Viswanadhapalli; Bridgitte Palacios; Salvador Alejo; Yihong Chen; Yi He; Uday P Pratap; Junhao Liu; Yi Zou; Zhao Lai; Takayoshi Suzuki; Andrew J Brenner; Rajeshwar R Tekmal; Ratna K Vadlamudi; Gangadhara R Sareddy
Journal:  Breast Cancer Res Treat       Date:  2020-10-14       Impact factor: 4.872

3.  Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis.

Authors:  Hanxiao Xu; Yijun Tian; Xun Yuan; Yu Liu; Hua Wu; Qian Liu; Gen Sheng Wu; Kongming Wu
Journal:  Onco Targets Ther       Date:  2016-01-21       Impact factor: 4.147

4.  Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors.

Authors:  Fang Yang; Lulu Cao; Zijia Sun; Juan Jin; Hehui Fang; Wenwen Zhang; Xiaoxiang Guan
Journal:  Int J Biol Sci       Date:  2016-12-07       Impact factor: 6.580

Review 5.  Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness.

Authors:  Rinad Mahmoud; Paloma Ordóñez-Morán; Cinzia Allegrucci
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

6.  STAT3 activation by leptin receptor is essential for TNBC stem cell maintenance.

Authors:  Praveena S Thiagarajan; Qiao Zheng; Manvir Bhagrath; Erin E Mulkearns-Hubert; Martin G Myers; Justin D Lathia; Ofer Reizes
Journal:  Endocr Relat Cancer       Date:  2017-08       Impact factor: 5.678

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.